Evidence map›Paper›PMID 24782834›Full record

ReviewFrontiers in microbiology2014

New insights into an X-traordinary viral protein.

Torsten Schaller, Hélène Bauby, Stéphane Hué, Michael H Malim, Caroline Goujon

Abstract readReview
In one paragraph

Review in Frontiers in microbiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Vpx overcomes a SAMHD1-independent block to HIV reverse transcription that is specific to resting CD4 T cells.Proceedings of the National Academy of Sciences of the United States of America · 2017
    Article
  7. Review
  8. Article
  9. Article
  10. SAMHD1's protein expression profile in humans.Journal of leukocyte biology · 2015
    Article
  11. Article
  12. Article
  13. The cytoplasmic tail of retroviral envelope glycoproteins.Progress in molecular biology and translational science · 2015
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Torsten SchallerDepartment of Infectious Diseases, King's College London London, UK.
Hélène BaubyDepartment of Infectious Diseases, King's College London London, UK.
Stéphane HuéDepartment of Infection, Division of Infection and Immunity, Centre for Medical Molecular Virology, University College London London, UK.
Michael H MalimDepartment of Infectious Diseases, King's College London London, UK.
Caroline GoujonDepartment of Infectious Diseases, King's College London London, UK.

Funding

Medical Research Council G1000196Medical Research Council G1001081
6 · The paper itself

Abstract

Vpx is a protein encoded by members of the HIV-2/SIVsmm and SIVrcm/SIVmnd-2 lineages of primate lentiviruses, and is packaged into viral particles. Vpx plays a critical role during the early steps of the viral life cycle and has been shown to counteract SAMHD1, a restriction factor in myeloid and resting T cells. However, it is becoming evident that Vpx is a multifunctional protein in that SAMHD1 antagonism is likely not its sole role. This review summarizes the current knowledge on this X-traordinary protein.

Indexed as

HIV-1HIV-2interferon type Imyeloid cellsrestriction factorSAMHD1SIVsmmvpx

Identifiers

PMID24782834
PMCPMC3986551

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.